Cardium Completes Patient Evaluations for Phase IIb Clinical Study

Cardium Therapeutics announced that all patients enrolled in the Company’s Matrix clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.
Yahoo! Finance